Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 trade

Rhea-AI Filing Summary

Gilead Sciences Chief Financial Officer sells shares under trading plan

Gilead Sciences CFO Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at $125.40 per share. After the sale, he directly holds 171,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Insights

Equity compensation and insider-trading analyst

CFO’s pre-planned sale is small relative to remaining stake.

Gilead Sciences CFO Andrew D. Dickinson executed an open-market sale of 3,000 common shares at $125.40 per share. Following this trade, he continues to hold 171,646 shares directly, indicating that only a small portion of his equity position was sold.

The filing notes the sale occurred under a Rule 10b5-1 trading plan adopted on August 29, 2024. Such plans are pre-arranged, helping separate routine liquidity or diversification from discretionary market-timing decisions and generally reducing the informational weight of the trade’s timing for investors.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares ($376,200)

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 3,000 shs ($376K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$125.40	$376K

Holdings After Transaction: Common Stock — 171,646 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 3,000 shares Sale price: $125.40 per share Shares held after sale: 171,646 shares +2 more

5 metrics

Shares sold 3,000 shares Open-market sale of common stock

Sale price $125.40 per share Price for 3,000 common shares sold

Shares held after sale 171,646 shares Direct holdings after transaction

Trading plan adoption date August 29, 2024 Rule 10b5-1 plan referenced in footnote

Net share direction -3,000 shares Net-sell across reported transactions

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

net-sell financial

"netBuySellDirection: net-sell"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		S(1)		3,000	D	$125.4	171,646	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Gilead Sciences (GILD) report for its CFO?

Gilead Sciences reported that CFO Andrew D. Dickinson sold 3,000 shares of common stock in an open-market transaction. The sale was recorded on a Form 4 insider filing and reflects an ordinary share sale rather than the exercise of derivatives or options.

At what price did the Gilead Sciences CFO sell his GILD shares?

The CFO’s reported sale was executed at an average price of $125.40 per share. This price applies to the 3,000 Gilead Sciences common shares sold in the open market, as disclosed in the Form 4 insider trading report filed with regulators.

How many Gilead Sciences (GILD) shares does the CFO hold after this sale?

After selling 3,000 shares, CFO Andrew D. Dickinson directly holds 171,646 Gilead Sciences common shares. This remaining stake, disclosed in the Form 4, shows that only a relatively small portion of his overall direct holdings was sold in this transaction.

Was the Gilead Sciences CFO’s GILD share sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transaction was made under a Rule 10b5-1 trading plan adopted on August 29, 2024. Such pre-arranged plans are designed to allow insiders to sell shares on a scheduled basis, reducing concerns about discretionary timing.

Does the Gilead Sciences Form 4 show any option exercises or derivative transactions?

No derivative transactions are listed in this Form 4. The filing reports only one non-derivative transaction: an open-market sale of 3,000 Gilead Sciences common shares, with no exercises or conversions of options or other derivative securities disclosed in the derivative section.